Long Lasting Efficacy in Patients with Plaque-Psoriasis Under Treatment with Certolizumab Pegol for 48 Weeks: Pooled Results from Multicentric, Randomized, Placebo Controlled Phase III Studies (CIMPASI-1, CIMPASI-2 and CIMPACT)

Authors

M Augustin
J Weglowska
M Lebwohl
C Paul
V Piguet
H Sofen
A Blauvelt
L Pererson
R Rolleri
K Reich
D Thaci
C Leonardi
Y Poulin
C Arendt
Alice Gottlieb, New York Medical CollegeFollow

Author Type(s)

Faculty

Document Type

Abstract

Publication Date

5-2019

Journal Title

Journal Der Deutschen Dermatologischen Gesellschaft

Department

Dermatology

Recommended Citation

Augustin, M., Weglowska, J., Lebwohl, M., Paul, C., Piguet, V., Sofen, H., Blauvelt, A., Pererson, L., Rolleri, R., Reich, K., Thaci, D., Leonardi, C., Poulin, Y., Arendt, C., & Gottlieb, A. (2019). Long Lasting Efficacy in Patients with Plaque-Psoriasis Under Treatment with Certolizumab Pegol for 48 Weeks: Pooled Results from Multicentric, Randomized, Placebo Controlled Phase III Studies (CIMPASI-1, CIMPASI-2 and CIMPACT). Journal Der Deutschen Dermatologischen Gesellschaft, 17 (Suppl. 3), 119-120. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/291